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1ABSTRACT
Clinicopathologic features and molecular characteristics of glucose 
metabolism contributing to 18F-fluorodeoxyglucose uptake in 
gastrointestinal stromal tumor
Min-Hee Cho
Department of Medical Science
The Graduate School, Yonsei University
(Directed by Professor Hoguen Kim)
Fluorine-18 fluorodeoxyglucose (18F-FDG) positron emission 
tomography–computed tomography (PET/CT) is useful in the preoperative 
diagnosis of gastrointestinal stromal tumors (GISTs); however, the molecular 
characteristics of glucose metabolism of GIST are unknown. We evaluated 
18F-FDG uptake on preoperative PET/CT of 40 patients and analyzed the 
expression of glycolytic enzymes in resected GIST tissues by qRT-PCR, 
western blotting, and immunohistochemistry. Results of receiver operating 
2characteristic curve analysis showed that the maximum standardized uptake 
value (SUVmax) cut-off value of 4.99 had a sensitivity of 89.5%, specificity 
was 76.2%, and accuracy of 82.5% for identifying tumors with a high risk of 
malignancy. We found that 18F-FDG uptake correlated positively with tumor 
risk grade and expression levels of glucose transporter 1 (GLUT1), hexokinase 
1 (HK1), and lactate dehydrogenase A (LDHA). Overexpression of GLUT1 and 
HK1 increased with higher tumor risk grade. In addition, overexpression of 
glycolytic enzymes M2 isoform of pyruvate kinase (PKM2) and LDHA was 
observed in GISTs, especially in high-risk tumors. These results indicate 
increased glycolysis in GISTs and suggest that upregulation of GLUT1, HK1, 
PKM2, and LDHA may play an important role in GIST tumorigenesis and may 
be useful in the preoperative prediction of malignant potential.
------------------------------------------------------------------------------------------------
Key words: gastrointestinal stromal tumors, 18F-FDG uptake, glucose 
metabolism, malignancy
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I. INTRODUCTION
Gastrointestinal stromal tumors (GISTs), the most common non-epithelial 
neoplasms of the gastrointestinal (GI) tract, are defined as “KIT or PDGFRA 
mutation-driven mesenchymal tumors that can occur anywhere in the GI tract”.1
Preoperative diagnosis of GISTs and assessment of their malignant potential are 
difficult because most GISTs are located in the submucosa. Tumor grading is 
therefore based primarily on mitotic index and tumor diameter. 
4The clinical usefulness of 18F-fluorodeoxyglucose (FDG) positron emission 
tomography–computed tomography (PET/CT) has been demonstrated in tumor 
staging, treatment response assessment, and prognosis prediction in various 
tumors.2-6 This technique is also used in tumor staging and evaluation of 
targeted therapy response in GISTs.7-12
Many tumors depend on aerobic glycolysis for rapid growth beyond that 
supported by the vasculature. 18F-FDG is an analogue of glucose that allows 
noninvasive evaluation of the tumor’s glucose metabolism, which can predict 
treatment response and patient prognosis. 18F-FDG enters the cell through 
glucose transporters (GLUT), is phosphorylated to 18F-FDG-6-PO4 by 
hexokinase (HK), and is then “trapped” in the cell as it is not further 
metabolized, allowing PET/CT acquisition 1 hour after 18F-FDG injection. 
Upregulation of GLUT and HK expression is associated with increased glucose 
metabolism and 18F-FDG uptake in tumors. For example, previous studies have 
shown that increased GLUT1 expression correlates with higher 18F-FDG uptake 
in lung and breast carcinomas.13-15
Although 18F-FDG PET/CT is useful for the preoperative diagnosis of GISTs, 
the detailed molecular mechanisms underlying glucose metabolism in these 
tumors and specific characteristics associated with tumor risk grade are not well 
5understood. Tumor cells consume large amounts of glucose and produce large 
amounts of lactate compared to normal cells, even in the presence of oxygen. 
This metabolic switch from oxidative phosphorylation to increased glycolysis 
(i.e., the Warburg effect) is a common characteristic of malignant tumors16,17
and regulated by transcription factors, such as hypoxia inducible factor-1α 
(HIF-1α), v-myc avian myelocytomatosis viral oncogene homolog (c-Myc), and 
tumor suppressor p53 (p53).18-20 In gastric cancer, 18F-FDG accumulation 
represents tissue hypoxia, rather than GLUT expression.21 However, analysis of 
the enzymes involved in glycolysis has not been performed in GISTs, and it is 
unclear whether the Warburg effect occurs in GISTs. Qualitative and 
quantitative analysis of glycolytic enzyme expression and their relationship with 
GIST tumor risk grade may clarify whether the Warburg effect occurs in GISTs. 
In this study, we aimed to identify 1) the relationship between maximum 
standardized uptake value (SUVmax) on preoperative 18F-FDG PET/CT with 
GLUT and HK expression in GISTs, 2) the specific isoforms of GLUT and HK 
that are upregulated according to GIST tumor risk grade, and 3) alterations in 
the expression of various glycolytic enzymes according to tumor risk grade. 
By performing this study, we expect to identify the molecular biomarkers 
predictive of malignant GISTs that can be used in preoperative biopsy or 
6cytology specimens and the molecular mechanisms of GIST detection by 
18F-FDG PET/CT.
7II. MATERIALS AND METHODS
1. Patient selection
Our patient selection criteria specified the inclusion of patients diagnosed with 
GIST who underwent surgery after preoperative 18F-FDG PET/CT, and a total 
of 40 GIST patients were included in our study. The cases were identified 
prospectively and consecutively between 2003 and 2013 at Severance Hospital, 
Yonsei University College of Medicine and from the Liver Cancer Specimen 
Bank, National Research Resource Bank Program of the Korea Science and 
Engineering Foundation of the Ministry of Science and Technology. Written 
informed consent for use of GIST tissues was obtained from all patients, and 
use of these tissues for research purposes was approved by the Institutional 
Review Board of Yonsei University of College of Medicine. Risk of 
malignancy was categorized according to the system described by Fletcher et 
al.22
2. Mutational analysis
DNA extraction was performed by using the QIAamp DNA FFPE Tissue Kit 
(Qiagen, GmbH, Hilden, Germany) according to the manufacturer’s instructions. 
The Primers used to amplify v-kit Hardy-Zuckerman 4 feline sarcoma viral 
8oncogene homolog (KIT) exons are EXON9, 5’-AGT ATG CCA CAT CCC
AAG TG-3’ (forward) and 5’-TGA CTG ATA TGG TAG ACA GAG CC-3’
(reverse); EXON11, 5’-GGC ATG ATG TGC ATT ATT GTG-3’ (forward) and 
5’-TGG CAA ACC TAT CAA AAG GG-3’ (reverse); EXON13, 5’-ATG CGC
TTG ACA TCA GTT TG-3’ (forward) and 5’-AAG CAG TTT ATA ATC TAG
CAT TGC C-3’ (reverse); and EXON17, 5’-TGT GAA CAT CAT TCA AGG
CG-3’ (forward) and 5’-AAA TGT GTG ATA TCC CTA GAC AGG-3’ (reverse).
PCR was carried out using a Veriti thermal cycler (Life Technologies, USA) 
with the following amplification conditions: 35 cycles of denaturation at 94°C
for 30 sec, annealing at 60°C for 30 sec, and extension at 72°C for 1 min. The 
amplified products were purified using Agencourt AMPure XP (Beckman 
Coulter Genomics, Danvers, MA), and direct sequencing was performed using 
the BigDye Terminator Ready Reaction Cycle Sequencing kit and an ABI Prism 
3130 genetic analyzer (Life Technologies).
3. PET/CT protocol and quantification
All patients underwent routine 18F-FDG PET/CT scans with either the DSTe 
PET/CT scanner (GE Healthcare, Milwaukee, WI) or the Biograph TruePoint 40 
PET/CT scanner (Siemens Medical Systems, CTI, Knoxv/ille, TN). Before 
918F-FDG injections, all patients fasted for at least 6 hr, and peripheral blood 
glucose levels were confirmed to be ≥140 mg/dL. The 18F-FDG dose of 
approximately 5.5 MBq/kg body weight was administered intravenously 1 hour 
before image acquisition. After the initial low-dose CT (DSTe: 30mA, 130 kVp, 
Biograph TruePoint: 36 mA, 120 kVp), standard PET imaging was performed 
from neck to the proximal thighs (acquisition time, 3 min/bed) in 
three-dimensional mode. Images were then reconstructed using ordered-subset 
expectation maximization (2 iterations, 20 subsets). 
Images were reviewed by an experienced nuclear medicine specialist on a GE 
AW 4.0 workstation. On PET scans, a volume of interest (VOI) was drawn on 
the primary lesion; SUVmax of the GIST was recorded.
4. Immunohistochemistry
Formalin-fixed and paraffin-embedded GIST tissue specimens were cut into 
4-μm thick sections, and immunohistochemistry (IHC) analysis was performed 
using the Ventana Discovery XT autoimmunostainer (Ventana, Tucson, AZ) 
with antibodies against GLUT1 (1:100; Millipore, Temecula, CA), HK1 (1:800; 
Cell Signaling Technology, Beverly, MA), PKM2 (1:500; Cell Signaling 
Technology), and LDHA (1:100; Cell Signaling Technology). IHC results were 
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scored based on staining intensity as follows: 0, no staining; 1, weak staining 
(faint protein expression in tumor cells or definite expression in <30% of tumor 
cells); or 2, strong staining (definite protein expression in >30% of tumor cells).
5. Western blotting
Whole lysates from GIST tissues were prepared using passive lysis buffer 
(Promega, Madison, WI) with a protease inhibitor cocktail (Roche, Mannheim, 
Germany). Total protein lysates (50㎍) were loaded into each lane, 
size-fractionated by SDS-PAGE and transferred to a nitrocellulose membrane 
that was blocked with Tris-buffered saline-Tween 20 containing 5% skim milk. 
Primary antibodies against GLUT1 (1:500; Millipore), HK1 (1:1,000; Cell 
Signaling Technology), PKM2 (1:1,000; Cell Signaling Technology), LDHA 
(1:1,000; Cell Signaling Technology), β-actin (1:2,000; Cell Signaling 
Technology), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH, 
1:100,000; Trevigen, Gaitherburg, MD) were incubated with the membrane for 
overnight at 4℃. After washing, membranes were incubated with goat 
anti-rabbit or mouse IgG-HRP conjugated secondary antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA), washed, and then developed using western 
blotting luminol reagent (Santa Cruz Biotechnology). Protein band intensity 
11
was analyzed by using a LAS-4000 Mini camera (Fujifilm, Tokyo, Japan). 
6. Quantitative reverse transcription-polymerase chain reaction 
Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) 
analysis was carried out in a final reaction volume of 20 μl with Premix Ex Taq
II (Takara Bio, Otsu, Japan) according to the manufacturer’s protocol. All 
reactions were run in triplicate on the StepOnePlus Real-Time PCR System 
(Applied Biosystems, Foster City, CA). Primer sequences are as follows: 
Beta-actin, 5’-GGA CCT GAC TGA CTA CCT CAT-3’ (forward) and 5’-CGT
AGC ACA GCT TCT CCT TAA T-3’ (reverse); GLUT1, 5’-CTC CTG CCC
TGT TGT GTA TAG-3’ (forward) and 5’-CAG GAG TGA GGT GGT GTA
TTT-3’ (reverse); GLUT2, 5’-CTA AAG GGC AGG TGG TTC TAA T-3’
(forward) and 5’-TTG CAT CCT CAG GTT TCT AGT T-3’ (reverse); GLUT3, 
5’-GCT GGG CAT CGT TGT TGG A-3’ (forward) and 5’-GCA CTT TGT
AGG ATA GCA GGA AG-3’ (reverse); GLUT4, 5’-GGC TTC TTC ATC TTC
ACC TTC T-3’ (forward) and 5’-GGT TTC ACC TCC TGC TCT AAA-3’
(reverse); HK1, 5’-CAC ATT GAT CTG GTG GAA GGA-3’ (forward) and 
5’-CTC TGT CCG GAT GTC TTC TAA TG-3’ (reverse); HK2, 5’-AGC CAC
CAC TCA CCC TAC TGC-3’ (forward) and 5’-CTG GAG CCC ATT GTC
12
CGT TAC-3’ (reverse); PKM2, 5′-ATT ATT TGA GGA ACT CCG CCG
CCT-3′ (forward) and 5′-ATT CCG GGT CAC AGC AAT GAT GG-3′
(reverse); LDHA, 5’-ACC CAG ATT TAG GGA CTG ATA AAG-3’ (forward) 
and 5’-CCA ATA GCC CAG GAT GTG TAG-3’ (reverse).
7. Hexokinase and lactate dehydrogenase activity assay
Hexokinase (HK) and lactate dehydrogenase (LDH) activities in GIST tissues 
were determined using a colorimetric (450 nm) kit (Sigma-Aldrich, St Louis, 
MO) according to the manufacturer’s recommended protocol. Each sample was 
diluted as necessary to fall in the linear range of the standard curve and assayed 
in duplicate. Briefly, 10 μl samples were mixed with assay buffer in HK activity 
assay and 5 μl samples were mixed with assay buffer in LDH activity assay. 
Absorbance was measured at room temperature every 5 min (HK activity) and 
at 37°C every 2-3 min (LDH activity). Both enzyme activities were assessed 
using the following equation: B × sample dilution factor/(Tfinal - Tinitial) × V; 
where B is the amount of NADH generated between Tinitial and Tfinal, and (Tfinal -
Tinitial) indicates the reaction time. V is the sample volume (mL) added to the 
reaction well.
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8. Statistical analysis
Relationships between tumor risk grade and other parameters were evaluated 
using either chi-square test or one-way analysis of variance. Correlation 
analysis was performed with Pearson’s or Spearman’s correlation test. Student’s 
t-test was used to compare two groups of continuous variables. The area under 
the receiver operating characteristic (ROC) curve was used to determine the 
SUV cut-off level able to predict tumor risk grade with the highest sensitivity. 
Data are expressed as mean ± standard deviation (SD); P<.05 was considered 
significant. Statistical analysis was performed using SPSS for Windows 
(version 21.0; SPSS Inc., USA).
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III. RESULTS
1. Clinicopathologic characteristics and 18F-FDG uptake of 40 GISTs
Of the 40 patients included in the study, 22 were women and 18 were men , and 
mean patient age was 59 yr (range 20–83) (Table 1). Of the 40 GIST lesions, 18 
were located in the stomach, 22 were located in the small or large intestine.
Five lesions were not well visualized on PET (SUVmax<2.5), 12 showed 
moderate FDG uptake (2.5<SUVmax<5.0), and 23 showed intense FDG uptake 
(SUVmax≥5.0). High-risk tumors were more common in men (Table 2). FDG 
uptake did not differ significantly between gastric GISTs and non-gastric GISTs 
(data not shown). Histologic features of representative cases are shown in 
Figure 1A.
KIT mutations were found in 32 cases (32/40, 80%). No mutations of KIT gene 
were found in the remaining 8 cases. Among the 32 mutations in KIT, a deletion 
was found in 19 cases (19/32, 59.4%), point mutations in 9 (9/32, 28.1%), and 
insertion in 4 (4/32, 12.5%) (Table 1). Relationships between mutation status of 
KIT and clinicopathologic parameters were analyzed and listed on Table 3.
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Table 1. Demographic and clinicopathologic features of 40 patients with 
GISTs
Tumor Mutation status       
No. Age Sex Site SUVmax KIT
1 66 Male Stomach 5.7 K550_V555 del
2 46 Female Jejunum 4.5 M552_D572 del
3 71 Male Stomach 5.2 V559D
4 67 Male Stomach 12.4 M552_Y553 del
5 65 Female Ileum 16.9 Y503_F504 ins AY
6 58 Male Stomach 12.5 K558_E562 del
7 65 Female Jejunum 19.2 M552_I571 del
8 53 Male Stomach 8.9 W557_K558 del
9 56 Male Jejunum 9.2 wild
10 77 Male Ileum 14.7 Y503_F504 ins AY
11 54 Male Stomach 12.0 V559D
12 71 Male Stomach 21.4 Q556_K558 del
13 58 Female Rectum 8 wild
14 49 Male Jejunum 5.4 Y568_L576 del
15 66 Male Stomach 14.5 W557_K558 del
16 27 Male Jejunum 14.2 W557_V560 del
17 60 Female Stomach 3.2 D579 del
18 35 Female Ileum 6.7 Q556_V560 del
19 65 Female Stomach 13 wild
20 69 Female Stomach 8.1 K558_I563 del
21 22 Female Stomach 5.0 T574_K581 del
22 73 Female Stomach 4.9 W557R
23 83 Female Stomach 2.4 wild
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24 67 Female Duodenum 9.5 Y503_F504 ins AY
25 75 Male Jejunum 2.9 wild
26 49 Female Stomach 2.9 wild
27 54 Female Duodenum 7.9 W557_K558 del
28 64 Female Ileum 10.1 Y503_F504 ins AY
29 53 Female Jejunum 2 wild
30 20 Female Duodenum 3.9 W557_K558 del
31 58 Male Jejunum 2.2 V560 del
32 69 Male Jejunum 4.8 wild
33 52 Female Duodenum 4.3 V560D
34 75 Male Duodenum 2.9 V559D
35 59 Male Duodenum 1.8 D572Y
36 57 Female Stomach 2.6 L576P
37 62 Female Stomach 3.7 L576P
38 65 Female Duodenum 2.6 W557_K558 del
39 64 Male Stomach 2.4 V560D
40 49 Female Jejunum 12.2 W557_K558 del
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Table 2. Relationships between GIST risk grade and 18F-FDG uptake and 
demographic and clinicopathologic factors
Low
(n=13)
Intermediate
(n=8)
High
(n=19) P value
Age, years 57.5±13.3 61.5±19.4 58.4±12.5 0.814
Gender, n
Male 5 1 12 0.046*
Female 8 7 7
Tumor size, cm 3.2±1.0 5.9±2.1 9.6±4.0 <.001*
Mitotic count, /50 HPF 2.1±1.3 4.9±3.5 27.5±35.2 0.013*
SUVmax 4.3±3.2 5.4±2.7 10.9±5.2 <.001*
*P value was calculated either by chi-square test or one-way analysis of 
variance
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Figure 1. Histologic features of GISTs and Representative cases showing 
18F-FDG uptake intensity according to tumor risk grade. (A) Low-risk GIST 
showing proliferation of bland-looking spindle cells with infrequent mitoses 
(1/50 HPFs) (left panel). Intermediate-risk GIST showing mild nuclear 
pleomorphism (dashed line) with occasional mitosis (10/50 HPFs; black arrows) 
(middle panel). High-risk GIST showing proliferation of spindle cells with 
hyperchromatic nuclei (white arrows), moderate pleomorphism, and frequent 
mitoses (13/50 HPFs) (right panel). Scale bar, 100μm; ×200. (B) Low-risk 
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GIST: 58-year-old man with mild 18F-FDG uptake (SUVmax=2.2) in the 
proximal jejunum (left panel). Intermediate-risk GIST: 73-year-old woman with 
moderate 18F-FDG uptake (SUVmax=4.9) (middle panel). High-risk GIST: 
65-year-old woman with intense 18F-FDG uptake (SUVmax=19.2) (right panel).
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Table 3. Comparison of clinicopathologic categories between GISTs with 
KIT mutation
Mutation status of KIT
Category
Wild
(n=8)
Exon 11
(n=28)
Exon 9
(n=4) P value
Age, years 63.5±11.7 56.0±14.7 68.3±6.0 0.146
Gender, n
Male 3 14 1 0.574
Female 5 14 3
Tumor size, cm 7.6±4.2 6.6±4.3 6.3±2.2 0.818
Mitotic count, 
/50 HPF
19.8±28.4 14.0±28.7 9.8±7.6 0.812
Tumor site, n
stomach 3 15 0 0.117
non-stomach 5 13 4
Tumor grade
Low 2 10 1 0.692
Intermediate 3 4 1
High 3 14 2
GLUT1
Negative 1 3 0 0.126
Positive 6 20 1
Strong 1 5 3
HK1
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Negative 1 4 0 0.124
Positive 6 19 1
Strong 1 5 3
PKM2
Negative 2 5 1 0.966
Positive 5 18 2
Strong 1 5 1
LDHA
Negative 0 0 0 0.162
Positive 4 14 0
Strong 4 14 4
SUVmax 5.6±4.0 7.5±5.3 12.8±3.6 0.074
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2. Correlation between 18F-FDG uptake and tumor risk grade
Tumor risk grade 22 correlated significantly with 18F-FDG uptake (P<.001) 
(Table 2 and Figure 1B). SUVmax was lower for low-risk (4.3±3.2) and 
intermediate-risk tumors (5.4±2.7) than for high-risk tumors (10.9±5.2; 
P<.001). 
To evaluate the usefulness of 18F-FDG PET/CT in predicting the malignant 
potential of GISTs, we compared high-risk tumors with intermediate- and 
low-risk tumors. ROC curve analysis showed that a SUVmax cut-off of 4.99 
was the most sensitive for predicting malignancy, and area under curve was 
0.875 (P<.001). Using this SUVmax cut-off value to differentiate high-risk 
tumors from low- and intermediate-risk tumors, sensitivity was 89.5% (16/18), 
specificity was 76.2% (17/22), and accuracy was 82.5% (32/40).
3. Overexpression of GLUT1 and HK1 in GISTs according to tumor 
risk grade
Because isoforms of GLUT and HK are overexpressed in tumors and associated 
with 18F-FDG uptake, we evaluated the expression of four isoforms of GLUT 
(GLUT 1, 2, 3, and 4) and two isoforms of HK (HK1 and HK2) in the 40 
GISTs. First, we analyzed total HK activity. We found that HK activity was 
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significantly upregulated in high-risk GISTs, compared to low-risk and 
intermediate-risk GISTs (P<.05) (Figure 2). Results of qRT-PCR analysis 
showed gradual increases in GLUT1 and HK1 expression with higher tumor 
risk grade (Figure 3). In contrast, expression of GLUT 2, 3, 4, and HK2 was not 
correlated with tumor risk grade at the mRNA level. Expression of GLUT1 was 
significantly increased in high-risk GISTs (1.3±1.32) compared to low-risk 
GISTs (0.27±0.32; P<.01). Similarly, HK1 expression was increased in 
intermediate-risk (1.65±0.48) and high-risk GISTs (1.58±1.10) compared to 
low-risk GISTs (0.94±0.68; P<.05).
Figure 2. Total HK activity in GISTs. Elevated HK activity is found in 
high-grade GISTs. Results are expressed as mean±SD of three independent 
experiments. *P<.05 based on the Student’s t-test.
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Figure 3. GLUTs (GLUT1, 2, 3, and 4) and HKs (HK1 and 2) expression 
according to GIST risk grade, as assessed by quantitative RT-PCR. GLUT1 
and HK1 mRNA levels increased with higher tumor risk grade. L=low risk; 
I=intermediate risk; H=high risk. *P<.05; **P<.01 based on the Student’s t-test.
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We next analyzed GLUT1 and HK1 protein expression by IHC and western blot 
analysis. GLUT1 and HK1 protein were detected in most GISTs; however, 
GLUT1 was not detected in four GISTs, and HK1 was not detected in five 
GISTs (Table 4). Most of the tumors lacking expression of these two proteins 
were low-risk GISTs (Table 4 and Figure 4A). Results of IHC staining showed 
that SUVmax correlated with both GLUT1 expression (rs=0.465, P=0.002) and
HK1 expression (rs=0.446, P=0.004) (Figure 4B). GLUT1 and HK1 expression 
were not affected by tumor size and mitotic count (Table 5). These findings 
suggest that GLUT1 and HK1 expression are related to PET signals. Results of 
western blotting analysis showed expression patterns of GLUT1 and HK1 that 
were similar to qRT-PCR and IHC results (Figure 4C).
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Table 4. Relationships between GLUT1 and HK1 immunohistochemical 
expression and GIST risk grade
Category
Low
(n=13)
Intermediate
(n=8)
High
(n=19) P value
GLUT1, n (%)
Negative 3 (23.1) 0 (0.0) 1 (5.3) 0.024*
Positive 10 (76.9) 7 (87.5) 10 (52.6)
Strong 0 (0.0) 1 (12.5) 8 (42.1)
HK1, n (%)
Negative 4 (30.8) 0 (0.0) 1 (5.3) 0.036*
Positive 9 (69.2) 6 (75.0) 11 (57.9)
Strong 0 (0.0) 2 (25.0) 7 (36.8)
*P value was calculated either by chi-square test or Fisher’s exact test.
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Figure 4. SUVmax correlated with GLUT1 and HK1 expression. (A) 
Immunohistochemical analysis of GLUT1 and HK1 expression in 
representative tumor tissues (×200). (B) Correlation between 18F-FDG uptake 
and GLUT1 and HK1 expression (rs=Spearman’s correlation coefficient). (C) 
Western blotting and densitometric analysis of GLUT1 and HK1 expression in 
representative tissues. The densitometric data are normalized to GAPDH and 
shown as arbitrary units. L=low risk; I=intermediate risk; H=high risk. *P<.05; 
**P<.01 based on the Student’s t-test.
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Table 5. Relationships between GLUT1 and HK1 immunohistochemical 
expression and tumor size and mitotic count
GLUT1 expression
Negative
(n=4)
Positive
(n=27)
Strong
(n=9) P value
Tumor size, cm 6.6±6.9 6.2±4.0 8.4±2.6 0.386
Mitotic count, 
/50 HPF
19.0±34.0 12.1±28.5 20.7±19.7 0.682
HK1 expression
Negative
(n=5)
Positive
(n=26)
Strong
(n=9) P value
Tumor size, cm 4.2±2.4 6.5±3.8 8.9±4.8 0.106
Mitotic count, 
/50 HPF
31.6±67.3 9.4±13.5 20.6±19.9 0.186
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4. Enhanced expression of PKM2 and LDHA in high-risk GISTs 
In order to elucidate the presence of the Warburg effect in GISTs, we evaluated 
mRNA and protein expression levels for PKM2 and LDHA. Results of 
qRT-PCR showed a gradual increase in PKM2 and LDHA expression with 
higher tumor risk grade (Figure 5). PKM2 expression was significantly higher 
in high-risk GISTs (3.39±3.51) than in low-risk (0.69±0.67) and 
intermediate-risk GISTs (0.85±0.36; P<.05). Similarly, LDHA expression was 
significantly higher in high-risk GISTs (1.37±1.09) than in low-risk (0.49±0.63)
and intermediate-risk GISTs (0.89±0.92; P<.05).
Figure 5. PKM2 and LDHA expression according to GIST risk grade, as 
assessed by quantitative RT-PCR. PKM2 and LDHA mRNA levels increased 
with higher tumor risk grade. L=low risk; I=intermediate risk; H=high risk. 
*P<.05 based on the Student’s t-test.
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Next, we evaluated protein levels of PKM2 and LDHA in the 40 GISTs by IHC 
and western blotting analysis. These two glycolytic enzymes were detected in 
most GISTs; however, PKM2 was not expressed in eight GISTs (Table 6). Most 
of the tumors lacking protein expression of these enzymes were low-risk GISTs. 
Protein levels of PKM2 and LDHA were increased in intermediate- and 
high-risk GISTs (Table 6 and Figure 6A). We also found a positive correlation 
between SUVmax and LDHA protein expression. SUVmax was significantly 
higher in tumors with strong LDHA expression than in tumors with weak 
LDHA expression (rs=0.466, P=0.002) (Figure 6B). Results of western blotting 
analysis showed that PKM2 and LDHA expression patterns were similar to IHC 
results (Figure 6C). Additionally, we measured LDH activity in our GIST 
tissues to evaluate metabolism status. LDH activity was significantly 
upregulated in high-risk GISTs, compared to low-risk and intermediate-risk 
GISTs (P<.01) (Figure 7). These findings suggest that upregulation of LDHA is 
involved in the malignant potential and PET signal of GISTs.
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Table 6. Relationships between PKM2 and LDHA immunohistochemical 
expression and GIST risk grade
Category
Low
(n=13)
Intermediate
(n=8)
High
(n=19) P value
PKM2, n (%)
Negative 6 (46.2) 1 (12.5) 1 (5.3) 0.02*
Positive 7 (53.8) 6 (75.0) 12 (63.2)
Strong 0 (0.0) 1 (12.5) 6 (31.6)
LDHA, n (%)
Negative 0 (0.0) 0 (0.0) 0 (0.0) 0.016*
Positive 10 (76.9) 3 (37.5) 5 (26.3)
Strong 3 (23.1) 5 (62.5) 14 (73.7)
*P value was calculated either by chi-square test or Fisher’s exact test.
32
Figure 6. SUVmax correlated with LDHA expression. (A) 
Immunohistochemical analysis of PKM2 and LDHA expression in 
representative tumor tissues. (B) Correlation between 18F-FDG uptake and 
PKM2 and LDHA protein expression (rs=Spearman’s correlation coefficient). 
(C) Western blotting and densitometric analysis of PKM2 and LDHA 
expression in representative tissues. The densitometric data are normalized to 
β-actin and shown as arbitrary units. *P<.05; **P<.01 based on the Student’s 
t-test.
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Figure 7. LDH activity in GISTs. Elevated LDH activity is found in 
high-grade GISTs. Results are expressed as mean±SD of three independent 
experiments. **P<.01 based on the Student’s t-test.
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IV. DISCUSSIONS
In this study, we evaluated clinicopathologic factors contributing to 18F-FDG 
uptake in the GISTs of 40 consecutive patients. Positive correlations were found 
between 18F-FDG uptake and several clinicopathologic features and metabolic 
factors. SUVmax correlated with expression of GLUT1, HK1, and LDHA; and 
NIH risk group. The optimal SUVmax cut-off value for identifying tumors with 
a high risk of malignancy (NIH risk classification) was 4.99 (sensitivity, 89.5%; 
specificity, 76.2%). These findings suggest that PET/CT may be useful for 
preoperative assessment of malignant potential.
We demonstrated significant overexpression of GLUT1 and HK1 protein in 
high-risk GISTs by IHC and western blot analysis. We also demonstrated that 
HK activity in upregulated in high-risk GISTs. GLUT and HK are important for 
glucose uptake, and the GLUT family of transporters has been implicated in 
18F-FDG uptake, with GLUT1 and GLUT3 in particular playing important roles 
in 18F-FDG accumulation.13,23 The role of HK in 18F-FDG uptake has been 
studied in various tumors.15,24,25 In our study, the isoforms GLUT1 and HK1 
were specifically overexpressed in high-risk GISTs, however, the expression 
levels of GLUT2, 3, 4, and HK2 showed no relationship with GIST risk grade.
Overexpression of GLUT1 in the cell membrane had been reported in many 
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tumors, and overexpression of GLUT2 and GLUT3 has been reported in 
hepatocellular carcinoma and malignant lymphoma, respectively.26,27 Although 
GLUT1, as well as GLUT3 and GLUT4, expression was found in one GIST cell 
line (GIST-T1),28 only the expression of GLUT1 was related to GIST risk grade.
The paired overexpression of GLUT1 and HK1 in GISTs, and the correlation 
between increased overexpression of these two proteins and tumor risk grade 
provide evidence for increased glucose uptake and abnormal glucose 
metabolism in GISTs, which may be useful in preoperative diagnosis and the 
development of novel therapeutic targets.
In this study, we demonstrated that the Warburg effect exists in GISTs and 
observed a correlation between 18F-FDG uptake and tumor risk grade. Most 
GISTs evaluated in this study showed significant overexpression of the 
glycolytic enzymes PKM2 and LDHA, with the degree of overexpression 
increasing with higher tumor risk grade. This metabolic switch from oxidative 
phosphorylation to increased glycolysis is one of the principle biochemical 
characteristics of malignant cells.16 In addition, PKM2 possesses protein 
tyrosine kinase activity and plays a role in modulating gene expression, thereby 
contributing to tumorigenesis.29 For example, enhanced PKM2 expression 
correlates with aggressive tumor behavior (in vivo tumor growth, tumor cell 
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proliferation, migration) in colon cancer.30 LDHA expression is also elevated in 
many types of cancers and is linked to tumor growth, maintenance, and 
invasion.31-34 Therefore, LDHA inhibition may restrict the energy supply in 
cancer cells, thereby decreasing their tumorigenicity.24,35 This enzyme may also 
be useful as a diagnostic marker or predictive biomarker for many types of 
cancer, as well as a therapeutic target for new anti-cancer treatments. In addition, 
the correlation between 18F-FDG accumulation and LDHA expression and the 
possible modulation of 18F-FDG uptake through LDHA-AKT-GLUT1 signaling 
has been reported in lung adenocarcinoma.24 Based on these reports, our 
findings showing overexpression of PKM2 and LDHA and the correlation 
between degree of expression and tumor risk grade in GISTs indicate that 
overexpression of PKM2 and LDHA may play important roles in GIST 
tumorigenesis and suggest their usefulness as potential therapeutic targets.
37
V. CONCLUSION
In conclusion, we evaluated the usefulness of preoperative 18F-FDG PET/CT for 
the prediction of malignant potential in GISTs and the relationship between 
tumor risk grade and the expression of proteins involved in glucose metabolism. 
Our results showed that 18F-FDG uptake correlates with tumor risk grade and 
expression levels of GLUT1, HK1, and LDHA. The increased expression of 
GLUT1, HK1, PKM2, and LDHA with higher tumor risk grades indicates 
important roles for these proteins in GIST tumorigenesis and suggests their 
usefulness in the preoperative prediction of malignant potential.
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ABSTRACT (IN KOREAN)
위장관기질종양에서 18F-fluorodeoxyglucose 섭취에 관여하는
당 대사 관련 유전자 발현 및 분자생물학적 특징
<지도교수 김 호 근>
연세대학교 대학원 의과학과
조 민 희
위장관기질종양은 중간엽 세포에서 발생된 육종으로, 주로 위장관계
의 벽의 점막하 조직에 존재한다. 이렇기 때문에 수술을 하기 전에는
병기의 결정 및 악성도를 평가하기에 한계점이 존재한다.
18F-fluorodeoxyglucose (18F-FDG) 를 이용한 양전자방출단층촬영
(positron emission tomography-computed tomography, PET/CT)은
위장관기질종양의 수술 전 진단, 예후 예측에 유용한 영상학적 기법
으로 쓰이고 있다. PET/CT는 종양이 정상 조직과 달리 비정상적인
증식을 위해 당 섭취를 증가시킨다는 것에 원리를 두고 있다. 그러나, 
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위장관기질종양에서 18F-FDG 섭취, 즉 포도당 대사에 어떠한 분자들
이 관여하는지에 대한 연구는 잘 알려지지 않았다. 18F-FDG PET/CT
의 판독은 표준 섭취 계수(standardized uptake value, SUV)의 측정
으로 당 대사 정도를 평가하여 양성 종양과 악성 종양을 구분하고 있
다.
본 연구에서는 위장관기질종양의 전반적인 당 대사를 이해하고자, 
PET/CT를 통하여 40명의 위장관기질종양 환자에 대한 18F-FDG 섭
취를 평가하였고, 40명의 환자에 해당하는 조직을 절제하여
qRT-PCR, western blotting, immunohistochemistry를 통해 당 분해
효소들의 발현을 분석하였다. 
ROC (receiver operating characteristic) curve 분석을 통하여
high-risk 종양 (악성)을 구분하기 위한 최대표준섭취계수의 cut-off 
값을 4.99로 좁혔다 (sensitivity, 89.5%; specificity, 76.2%; 
accuracy, 82.5%). 또한 당 분해과정에 관여하는 GLUT1, HK1, 
LDHA의 발현 정도와, 최대표준섭취계수가 양의 상관관계를 보이는
것을 확인하였다. 특히, 위장관기질종양의 high-risk 조직에서
GLUT1, HK1, PKM2, LDHA의 과발현을 확인하였다.
따라서 이러한 결과들은 GLUT1, HK1, PKM2, LDHA의 upregulation
이 위장관기질종양 형성 과정에 중요한 역할을 하며, 수술 전 위장관
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기질종양의 악성도 예측 지표로 유용하게 활용될 수 있을 것이라 기
대한다.
------------------------------------------------------------------------------------------------
핵심되는 말: 위장관 기질종양, 최대표준섭취계수, 악성도, 당 대사
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